Targeted thorium-227 conjugates as treatment options in oncology

HIGHLIGHTS

• who: Jenny Karlsson from the Oslo University Hospital, Norway University of Glasgow, United Kingdom have published the Article: Targeted thorium-227 conjugates as treatment options in oncology, in the Journal: (JOURNAL)
• what: The overall objective response rate (ORR) was 24% (5/21 patients: 1 complete and 4 partial responses), with the highest ORR seen in patients with relapsed low-grade lymphomas .
• future: A first-in-human Phase I study of MSLN-TTC in patients with advanced cancer (mesothelioma as well as MSLNpositive recurrent serous ovarian cancer and pancreatic adenocarcinoma) was completed in the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.